DELRAY BEACH, Fla., Sept. 17, 2024 /PRNewswire/ -- The human microbiome market is set to grow significantly, reaching USD 4,206 million by 2030 from USD 814.6 million in 2024, driven by a robust CAGR of 31.5%. Key factors propelling this growth include advancements in microbiome sequencing, collaborative research efforts, and a surge in startups and SMEs exploring microbiome-based solutions. However, challenges such as complex regulations, high commercialization costs, and slow patient adoption could impact market expansion. AI-driven technologies are transforming microbiome-based therapies by enabling personalized healthcare through precise data analysis. Notable players in this field include Biomica, which leverages AI for developing microbiome therapies. The market is characterized by a high number of startups and SMEs, significant investments in R&D, and a growing focus on personalized medicine. Challenges include the high cost of developing and commercializing microbiome drugs, evidenced by the discontinuation of Finch Therapeutics' fecal microbiota transplant. Opportunities lie in the rising demand for personalized medicine, with increasing awareness and advancements in microbiome diagnostics. The market is segmented by products, diseases, and regions, with North America leading in market share, followed by Europe and the fast-growing Asia Pacific region. Key market players include Seres Therapeutics, Ferring Pharmaceuticals, and BiomeBank, among others.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904
Browse in-depth TOC on "Human Microbiome Market"
250 - Tables
50 - Figures
300 - Pages
Drivers of Growth
The surge in the human microbiome market is largely driven by collaborative research efforts between the microbiome industry and academia, as well as the rise of start-ups and SMEs venturing into the microbiome sector. These smaller entities are attracting major investments thanks to their proprietary technologies, diverse product portfolios, and niche applications, distinguishing them from larger pharmaceutical companies. Their well-developed ecosystems for developing and commercializing microbiome therapies further support market growth.
Product Segmentation
In terms of product segments, Probiotics held the largest share of the human microbiome market in 2023, fueled by increasing consumer awareness of their benefits for gut health and overall wellness. Prebiotics followed as the second-largest segment. A notable trend is the rise of next-generation probiotics, which include probiotic strains from genera such as Bacteroides, Akkermasia, Faecalibacterium, and Eubacterium. These emerging probiotics offer new physiological benefits not seen in traditional strains.
Disease-Specific Insights
The human microbiome market is categorized into various disease segments, including infectious diseases, gastrointestinal diseases, endocrine and metabolic disorders, and cancer. Gastrointestinal diseases led the market in 2023, driven by the growing demand for personalized therapies and extensive regulatory approvals. The infectious diseases segment ranked second, propelled by FDA approvals for several Fecal Microbiota Transplant (FMT) products like VOWST, REBYOTA, and BIOMICTRA. Companies are increasingly targeting this segment, with a significant portion of microbiome drugs in the clinical pipeline focusing on infectious diseases.
Type-Based Segmentation
The Human Microbiome Market is segmented by types including Bacterial Consortia Transplantation (BCT)/Fecal Microbiota Transplantation (FMT), Peptide, Live Biotherapeutic Products, and others. Live Biotherapeutic Products held the largest market share in 2023, driven by high commercialization rates and the demand for personalized treatments. BCT/FMT followed as the second-largest segment, with recent approvals in the US and Australia bolstering its market presence. However, BCT/FMT faces global challenges including regulatory disparities, ethical issues, and safety concerns, underscoring the need for standardized practices and public education.
End-User Analysis
Among end users, Hospitals and Clinics captured the largest share of the human microbiome market in 2023. Hospitals provide controlled environments that ensure the efficacy and safety of microbiome therapies. The Other End Users segment held the second-largest share, reflecting diverse applications beyond traditional healthcare settings.
Regional Insights
The human microbiome market is divided into six regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America led the market in 2023, attributed to its established research infrastructure, technological advancements, high demand for precision medicine, supportive regulatory environment, and robust biotech and healthcare sectors. Europe followed as the second-largest market, while Asia Pacific is projected to be the fastest-growing region due to increasing awareness and emerging healthcare industries.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904
Market Structure
The human microbiome market is currently concentrated, with only two drugs approved in the US for preventing C. difficile infection: VOWST by Seres Therapeutics and Rebyota by Ferring Pharmaceuticals. Major players in the market include Seed Health, Inc., International Flavors & Fragrances, Inc., Seres Therapeutics, Ferring Pharmaceuticals, and Pendulum. These companies employ strategies such as new product launches, acquisitions, partnerships, and geographical expansions to enhance their market positions.
Key Player: Seres Therapeutics
Seres Therapeutics is an emerging leader in the human microbiome market, known for its advanced microbiome therapeutics platform that accelerates the development of new products. The company's R&D expenses were USD 145 million for 2023. Seres has formed collaborations with companies like Nestlé and Bacthera to advance clinical development and explore biomarker-based patient selection and stratification.
Key Player: Ferring Pharmaceuticals
Ferring Pharmaceuticals has seen revenue growth due to its pioneering approval of a fecal microbiota transplant product in the US. The company has leveraged both organic and inorganic growth strategies, including regulatory approvals, product launches, and collaborations, such as its December 2023 partnership with PharmaBiome. These efforts highlight Ferring's strong presence and innovation in the human microbiome market.
Key Player: Seed Health
Seed Health distinguishes itself with its unique synbiotic products and collaborations, including a partnership with the Swiss Institute of Allergy and Asthma Research (SAIF) to develop next-generation human microbiome products. The company's acquisition of augGI Technologies, Inc. underscores its commitment to integrating AI and machine learning technologies to enhance product adherence and outcomes. Seed Health's innovative approach positions it as a leader in advancing synbiotics and probiotics.
For more information, Inquire Now!
Related Reports:
High Throughput Screening Market
Clinical Microbiology Market
Microbiome Sequencing Services Market
Human Identification Market
Microbiome Diagnostics Market
Get access to the latest updates on Human Microbiome Companies and Human Microbiome Market Size
About MarketsandMarkets:
MarketsandMarkets has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/human-microbiome-market-to-hit-usd-4-206-million-by-2030-with-31-5-cagr--marketsandmarkets-302248855.html
